MGC018 With or Without MGA012 in Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

March 18, 2023

Study Completion Date

March 18, 2023

Conditions
Squamous Cell Carcinoma of Head and NeckTriple Negative Breast CancerMelanomaAdvanced Solid Tumor, AdultMetastatic Castrate Resistant Prostate CancerNon Small Cell Lung Cancer
Interventions
BIOLOGICAL

vobramitamab duocarmazine

Anti-B7H3 antibody drug conjugate

Trial Locations (21)

2010

St Vincent's Health Network (Kinghorn Cancer Centre), Darlinghurst

2298

Calvary Mater NewCastle, Waratah

3084

Austin Health - Olivia Newton John Cancer Center, Heidelberg

4105

The University of Queensland - Princess Alexandra Hospital (PAH), Woolloongabba

20016

Sibley Memorial Hospital, Washington D.C.

20850

Hospital Universitario HM Sanchinarro, Madrid

21231

The Johns Hopkins Kimmel Cancer Center, Baltimore

22031

Inova Schar Cancer Institute, Fairfax

Virginia Cancer Specialist, Fairfax

28034

Hospital Ruber Internacional, Madrid

28078

Carolina Biooncology Institute, Huntersville

49546

START Midwest, Grand Rapids

68114

Nebraska Methodist Hospital, Omaha

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90404

UCLA Department of Medicine - Hematology/Oncology, Santa Monica

31-501

Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Oddział Kliniczny Onkologii, Krakow

60-693

Med-Polonia Sp. z o.o., Poznan

01-748

Magodent Sp. z o.o. Szpital Elbląska Oddział Onkologii Klinicznej/ Chemioterapii, Warsaw

02-781

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Oddział Badań Wczesnych Faz, Warsaw

08035

Hospital Universitario Vall d'Hebron, Barcelona

Unknown

Institut Català D'Oncologia - Hospital Universitari Germans Trias I Pujol, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MacroGenics

INDUSTRY